- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.05. | OSR Holdings, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | OSR Holdings rules out reverse stock split amid Nasdaq compliance efforts | 3 | Investing.com | ||
| OSR HOLDINGS Aktie jetzt für 0€ handeln | |||||
| 12.05. | OSR Holdings, Inc.: CEO Statement to Shareholders | 288 | ACCESS Newswire | A Clear Commitment: No Reverse Stock Split BELLEVUE, WA / ACCESS Newswire / May 12, 2026 / As many of our shareholders are aware, OSR Holdings filed its Preliminary Proxy Statement on Schedule PRE 14A... ► Artikel lesen | |
| 05.05. | OSR Holdings, Inc.: Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target | 473 | ACCESS Newswire | NEW YORK, NY / ACCESS Newswire / May 5, 2026 / Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (Nasdaq:OSRH), reaffirming its Buy-Emerging rating and 12-month price target... ► Artikel lesen | |
| 30.04. | OSR Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.04. | OSR Holdings, Inc.: OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026 | 430 | ACCESS Newswire | OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026 BELLEVUE, WA / ACCESS Newswire / April 30, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding... ► Artikel lesen | |
| 30.04. | OSR Holdings Stock Surges Over 41% After Hours: Why Is It Moving? | 4 | Benzinga.com | ||
| 30.04. | OSR Holdings Executes $815 Million Global License Agreement For VXM01 With BCM Europe | 8 | pulse2.com | ||
| 29.04. | OSR Holdings licenses VXM01 to BCME for up to $815M in milestones | 5 | Investing.com | ||
| 29.04. | OSR Holdings, Inc.: OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe | 492 | ACCESS Newswire | Largest shareholder pledges entire equity stake as collateral for milestone obligations, reinforcing alignment with public shareholders BELLEVUE, WA / ACCESS Newswire / April 29, 2026 / OSR Holdings... ► Artikel lesen | |
| 22.04. | Yeiseok Kim wird neuer Chief Operating Officer bei OSR Holdings | - | Investing.com Deutsch | ||
| 22.04. | OSR Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 09.04. | OSR Holdings, Inc.: OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note | 372 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / April 9, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) ("OSR Holdings" or the "Company") today announced a strategic transaction for capital structure optimization with White... ► Artikel lesen | |
| 02.04. | OSR Holdings und BCM Europe: Neue Lizenzvereinbarung für VXM01 sichert Zahlungen von bis zu 815 Mio. $ | 3 | Investing.com Deutsch | ||
| 02.04. | OSR Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | OSR Holdings, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 30.03. | OSR Holdings, Inc.: OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026 | 224 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / March 30, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company advancing biomedical innovations to improve health and wellness worldwide, today... ► Artikel lesen | |
| 27.03. | Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target | 411 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / March 27, 2026 / Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (Nasdaq:OSRH), reaffirming its Buy-Emerging rating and 12-month price... ► Artikel lesen | |
| 23.03. | OSR Holdings, Inc.: OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level | 342 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / March 23, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced an updated structure of its previously disclosed binding term sheet dated January 13, 2026 with BCM... ► Artikel lesen | |
| 19.03. | OSR Holdings, Inc.: Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities | 589 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / March 19, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a healthcare-focused holding company advancing innovative medical technologies, today announced that its subsidiary... ► Artikel lesen |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,031 | +0,34 % | PacBio and Lucid Genomics Announce Compatibility Collaboration to Advance Tertiary Analysis for Long-Read Sequencing | MENLO PARK, Calif. & BERLIN, April 21, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a premier developer of sequencing solutions, and Lucid Genomics GmbH, a provider of cutting-edge bioinformatics... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,238 | +4,55 % | Wolfe Research initiates CytomX stock with outperform rating | ||
| CARISMA THERAPEUTICS INC | 0,028 | 0,00 % | Carisma Therapeutics Inc.: Carisma Announces Delisting from Nasdaq and SEC Deregistration | PHILADELPHIA, Dec. 5, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (OTCID: CARM) (the "Company") today announced that its Board of Directors (the "Board") has... ► Artikel lesen | |
| CAPRICOR | 25,790 | +3,41 % | Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary... ► Artikel lesen | |
| CORMEDIX | 6,988 | +2,40 % | CorMedix, Inc.: Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | ? Q1 2026 Net Revenue of $127.4 million ? ? Q1 2026 Net Income of $38.6 million; Adjusted EBITDA of $70.0 million ? - Company raises FY 2026 Revenue and Adjusted EBITDA Guidance - ? Conference Call... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 4,652 | +25,59 % | Minerva Neurosciences, Inc: Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference | BURLINGTON, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous... ► Artikel lesen | |
| REPLIMUNE | 4,554 | +2,92 % | Weekly Buzz: FDA Okays Travere Therapeutics, Royal Philips; Rejects Replimune; American Industrial Partners Snaps Up Avanos Medical; PDS Biotechnology, Hoth Therapeutics, Spyre Therapeutics, Paces Trials | INDIANAPOLIS (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S., Taiwan, and Europe, alongside FDA rejections, collaborations, acquisitions, and positive... ► Artikel lesen | |
| VALERIO THERAPEUTICS | 0,187 | -4,41 % | Valerio Therapeutics Announces Binding Term-Sheet for Collaboration and Exclusive License With Seed-Stage Biotech Company | Binding term-sheet for a potential aggregate amount of up to USD 200 million and tiered royalties
Regulatory News:
Valerio Therapeutics (FR0010095596 ALVIO), a biotechnology company specializing... ► Artikel lesen | |
| RANI THERAPEUTICS | 1,060 | -2,75 % | Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition | - Continued advancement of the ongoing Phase 1 study of RT-114 via RaniPill® for the treatment of obesity in collaboration with ProGen - - Appointed Alireza Javadi, Ph.D. as Chief Technical Officer... ► Artikel lesen | |
| IO BIOTECH | 0,048 | 0,00 % | IO Biotech Provides Corporate Update | Raymond James engaged as financial advisorReduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing... ► Artikel lesen | |
| ALTO NEUROSCIENCE | 21,110 | +3,03 % | Alto Neuroscience, Inc.: Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression | - Phase 2b closely resembles PAX-D study design, which demonstrated an effect size for pramipexole more than two times larger than approved TRD therapies - - Trial design and MADRS primary endpoint... ► Artikel lesen | |
| CERO THERAPEUTICS | 0,095 | +0,11 % | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial | Company to initiate third planned cohort at higher dose level, including patients with myelodysplastic syndrome and myelofibrosis SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- CERo... ► Artikel lesen | |
| QIAGEN | 30,095 | +0,62 % | QIAGEN N.V.: QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA | Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases Goal to advance how disease mechanisms... ► Artikel lesen | |
| RELAY THERAPEUTICS | 14,640 | +21,29 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen | |
| IMMUNOVANT | 34,140 | +29,86 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen |
OSR HOLDINGS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,010 (-1,90 %) liegt der Kurs bei 0,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OSR HOLDINGS INC finden Sie auf Wallstreet Online.